You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The funding, provided by the Chan Zuckerberg Initiative, will help test and study the Bay Area population in general as well as healthcare workers in particular.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.
In PLOS this week: CLCA2 expression linked to survival among African-American women with aggressive breast cancer, gene alterations linked to hearing loss, and more.
The company is working to develop another lab-based serology test to detect IgM antibodies in people who have already had the virus.
The firms plan to discover and develop fully human neutralizing antibodies that target the SARS-CoV-2 virus, combining Adaptive's and Amgen's respective expertise.
The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.
According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.
UK-based Abcam has also taken an undisclosed equity stake in BrickBio, located in Boston, and will work with the company to further develop its platform.
The collaborators are developing a sample prep solution for the Mission Bio Tapestri platform and are working on a hematology-focused panel.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.